8-K: OrthoPediatrics Secures $100 Million in Private Financing to Fuel Growth

OrthoPediatrics Corp. has entered into a private financing agreement with Braidwell LP, securing up to $100 million through a term loan and convertible notes.

Summary

• OrthoPediatrics Corp. has announced a private financing agreement with Braidwell LP, providing up to $100 million in capital.
• The financing includes a $50 million term loan and $50 million in convertible notes.
• The term loan consists of an initial $25 million and a delayed draw facility of $25 million, with interest at SOFR plus 6.50%, and an option for a 1.00% payment-in-kind interest.
• The term loan is interest-only until maturity in August 2029 and includes covenants to maintain cash reserves and minimum net product sales.
• The convertible notes, totaling $50 million, will accrue interest at 4.75% per annum, payable quarterly, and mature in February 2030.
• The notes are convertible into common stock at an initial price of $40.98 per share, a 30% premium to the recent average stock price.
• The company's board has approved a $5 million stock repurchase program, representing approximately 0.7% of outstanding common stock.
• The financing proceeds will be used to repay $10 million in existing debt, cover transaction fees, fund potential stock repurchases, and for general corporate purposes and working capital.
• Post-closing, OrthoPediatrics' pro forma cash balance would be approximately $90 million, excluding the delayed draw term loan.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment with the company securing significant funding and outlining strategic growth plans. The terms of the financing appear reasonable, and the stock repurchase program is a positive signal for investors.

Positives

• The financing strengthens the company's balance sheet and provides a more attractive cost of capital.
• The capital provides flexibility to execute strategic growth initiatives, including clinic expansion.
• The company expects to achieve cash flow breakeven with its current liquidity position.
• The stock repurchase program may increase shareholder value.

Negatives

• The term loan includes financial covenants that require maintaining cash reserves and minimum net product sales.
• The convertible notes are subject to conversion, which could dilute existing shareholders.

Risks

• The term loan and convertible note placement may not close as expected.
• The company's actual results may differ materially from forward-looking statements.
• The company is subject to risks and uncertainties detailed in its SEC filings.

Future Outlook

The company expects its current liquidity position will enable it to achieve cashflow breakeven and the financing will provide additional flexibility to execute strategic growth initiatives.

Management Comments

• This financing strengthens our balance sheet at a more attractive cost of capital.
• This capital also provides additional flexibility to execute our strategic growth initiatives where one of our top priorities is to be aggressive with OPSB clinic expansion at the remaining childrens hospitals across the country.
• We expect our current liquidity position will enable us to achieve cashflow breakeven and we appreciate Braidwell who is a great strategic partner that is invested in our future and growth strategy.
• We are excited to strengthen our partnership with OrthoPediatrics and to continue supporting their advancement of pediatric orthopedics.

Industry Context

This financing reflects a continued interest in the pediatric orthopedics market and provides OrthoPediatrics with the capital to expand its operations and product offerings.

Comparison to Industry Standards

• The interest rate on the term loan is consistent with current market rates for similar financings.
• The conversion premium on the convertible notes is a common feature in such transactions.
• The stock repurchase program is a typical method for companies to return value to shareholders.
• The pro forma cash balance is a positive indicator of the company's financial health.

Stakeholder Impact

• Shareholders may benefit from the stock repurchase program and the company's growth initiatives.
• Employees may benefit from the company's strengthened financial position and growth.
• Customers may benefit from the company's expanded product offerings and services.

Next Steps

• The financing is expected to close on or about August 12, 2024.
• The company will use the proceeds to repay debt, cover transaction fees, fund stock repurchases, and for general corporate purposes.
• The company will focus on OPSB clinic expansion at remaining children's hospitals.

Key Dates

Keywords

OrthoPediatrics, Braidwell LP, private financing, term loan, convertible notes, stock repurchase, pediatric orthopedics, capital raise, debt repayment, working capital